European Multicenter and Open-Label Controlled Randomized Trial to Evaluate the Efficacy of Sequential Treatment With Tacrolimus-Rituximab Versus Steroids Plus Cyclophosphamide in Patients With Primary Membranous Nephropathy (The STARMEN Study)
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 23 Feb 2019
Price : $35 *
At a glance
- Drugs Rituximab (Primary) ; Tacrolimus (Primary) ; Cyclophosphamide; Methylprednisolone; Methylprednisolone
- Indications Membranous glomerulonephritis
- Focus Therapeutic Use
- Acronyms STARMEN
- 03 Jan 2019 Planned End Date changed from 1 Apr 2019 to 30 Jun 2019.
- 03 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 30 Jun 2019.
- 03 Jan 2019 Status changed from recruiting to active, no longer recruiting.